Accelerated development of liver fibrosis in CCl4-treated rats by the weekly induction of acute phase response episodes: Upregulation of α1(I) procollagen and tissue inhibitor of metalloproteinase-1 mRNAs1This work was supported in part with Grants RO1 AA09231 and RO1 AA10541 from the National Institutes of Health.1  by Greenwel, Patricia & Rojkind, Marcos
 .Biochimica et Biophysica Acta 1361 1997 177–184
Accelerated development of liver fibrosis in CCl -treated rats by the4
weekly induction of acute phase response episodes: Upregulation of
 / 1a1 I procollagen and tissue inhibitor of metalloproteinase-1 mRNAs
Patricia Greenwel 2, Marcos Rojkind )
Di˝ision of Gastroenterology, Hepatology and Nutrition, Marion Bessin Li˝er Research Center, U-625 and Departments of Medicine and
Pathology, Albert Einstein College of Medicine, 1300 Morris Park A˝enue, Bronx, NY 10461, USA
Received 2 January 1997; revised 19 March 1997; accepted 20 March 1997
Abstract
 .Patients with alcoholic hepatitis have several manifestations of the acute phase response APR and have elevated blood
levels of interleukin-1, interleukin-6 and tumor necrosis factor-a. We have previously shown that liver stellate cells express
 .interleukin-6 mRNA and protein and respond to this cytokine with increased expression of a1 I procollagen mRNA. We
 .further showed that the production of an APR episode stimulates a transient expression of a1 I procollagen mRNA in the
liver. In this communication we demonstrate that the concomitant induction of a weekly APR episode in rats with a
schedule of CCl to produce cirrhosis, accelerates the development of liver fibrosis. We show that the enhancement of liver4
 .fibrosis is due, in part, to further upregulation in the expression of a1 I procollagen and tissue inhibitor of metallopro-
teinases-1 mRNAs above values observed in control rats receiving only CCl . The effect of the APR appears to have4
specificity since not all the mRNAs measured were equally affected. Altogether, these results suggest that increased blood
or liver levels of APR cytokines, whether induced by APR episodes, endotoxin or other unrelated causes, may contribute to
the development of liver fibrosis by enhancing the expression of type I collagen and of tissue inhibitor of metallopro-
teinases-1 mRNAs. q 1997 Elsevier Science B.V.
 .Keywords: Liver fibrosisrcirrhosis; Liver stellate cell; Acute phase response; Cytokine; Interleukin-6; a1 I procollagen; TIMP-1
1. Introduction
 .The acute phase response APR is a systemic
reaction of the organism to non-specific inflamma-
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tory stimuli. It is accompanied by fever, leukocytosis
and significant changes in several serum proteins
produced by the liver. These include a decrease in
serum albumin and an increase in fibrinogen, a 2-
w xmacroglobulin and a1 acidic glycoprotein 1,2 . The
expression of these proteins, which are referred to as
 .the acute phase proteins APRP , is regulated, among
 .other factors, by tumor necrosis factor a , TNF-a ,
 .  . w xinterleukin-6 IL-6 and interleukin-1 IL-1 1–7 .
These cytokines are produced by different cell types,
including blood monocytes and polymorphonuclear
cells, macrophages, endothelial, Kupffer cells and
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w xliver-stellate cells 1,5,6,8–11 . The modulation of
the expression of liver APRP is complex but, in many
instances, it has been shown that their expression is
w xregulated at the transcriptional level 3,4 . Data in the
literature strongly suggest that the APR may play a
key role in liver cirrhosis and fibrosis. Patients with
alcoholic hepatitis have several manifestations of the
APR and have elevated blood levels of the APR
w xcytokines IL-1, IL-6 and TNF-a 12–17 . The same
cytokines involved in the APR are produced by vari-
w xous liver cell populations 5,10,11,18–20 and modu-
late the expression of extracellular matrix compo-
nents by mesenchymal cells, including liver stellate
 . w xcells LSC 21 . These cells, are the main producers
w xof type I collagen in normal and cirrhotic liver 22 .
Our previous studies have suggested that cultured
LSC obtained from cirrhotic rat livers, when treated
 .with IL-6, respond with a greater increase in a1 I
procollagen mRNA than LSC from normal liver
w x10,21 . Thus, because LSC are active participants in
liver fibrogenesis and their collagen production is
modulated by the APR cytokines, we considered it
important to investigate the role of these cells in
collagen production in vivo in rats with an APR
episode. Our results showed that a single APR episode
 .suffices to induce the expression of a1 I procolla-
gen mRNA in the liver, and that the responding cells
w xare LSC 23 . Similar to the other systemic alterations
induced by an APR stimulus, all the changes were
shown to be transient and returned to normal levels
within 48–72 h. We now report the alterations in
 .a1 I procollagen and tissue inhibitor of metallopro-
 .teinases TIMP-1 mRNA expression in rats receiv-
ing a weekly APR stimulus alone or in combination
with a schedule of CCl , a substance known to4
induce liver fibrosis and cirrhosis. Our results showed
that the superimposition of an APR stimulus to ani-
mals with chronic CCl -liver injury enhances selec-4
 .tively the expression of liver a1 I procollagen and
TIMP mRNAs and accelerates the accumulation of
liver collagen.
2. Materials and methods
2.1. Experimental animals
30 male Sprague-Dawley rats weighing 80–100 g
were divided into 4 groups. The control group group
.1 , containing 6 rats, did not receive any treatment.
 .The acute phase group group 2 contained 8 animals
 .that received once a week 0.15 ml intradermally of
 .turpentine EM Science, Cherry Hill, NJ . The third
group consisted of 8 rats in which liver fibrosis was
induced by intraperitoneal administration of CCl in4
 .mineral oil 1:5 , 3 times per week as previously
w xdescribed 24 . Rats in group four consisted of 8
animals that received the combined treatment of CCl4
 .to produce cirrhosis see above , and a weekly intra-
dermal injection of 0.15 ml of turpentine. Rats were
sacrificed with ether 72 h after the ninth CCl dose4
andror 72 h after the last turpentine dose. A 4 mm
slice from the right lobe of each liver was removed
and fixed in 10% formalin; the remaining liver was
immediately frozen in liquid nitrogen and stored at
y708C until needed.
2.2. Quantitati˝e analysis of li˝er collagen
Collagen measurements were performed with trip-
licate 10 mm sections of paraffin-embedded, forma-
lin-fixed specimens after staining with Picrosirius red
w xand Fast green as previously described 25 except for
minor modifications. In brief, all the sections were
fixed onto one end of the slide, deparaffinized and
w xstained as described 25 . Slides were washed several
times with distilled water until the wash-fluid was
free of color and subsequently, the area surrounding
the section was cleaned with tissue paper. The two
 .dyes bound to collagen Sirius red and all other
 .proteins Fast green were eluted into a 1 ml cuvette
with 1 ml of a 1:1 solution of 1 N NaOH:methanol.
The absorbency of each dye at 540 and 605 nm
respectively, was determined and collagen concentra-
tion per mg protein calculated as previously de-
w xscribed 25 . Values are mean"SD of triplicate slides
of 3–4 livers.
2.3. RNA extraction and Northern blot analysis
Total RNA was extracted as described by Chom-
w xczynski and Sacchi 26 using frozen liver samples
weighing 25–50 mg. Aliquots containing approxi-
mately 15 mg of RNA were used for Northern blot
w x 32hybridization 10 . The following P-labeled cDNA
 . w x  . w xprobes were utilized: a1 I 27 and a1 III 28
w x w xprocollagens, fibronectin 29 , MMP2 30 and TIMP
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w x1 31 . Signal intensity was determined by laser
densitometric analysis of the X-rays using NIH image
software after scanning of the X-ray films with the
Adobe Photoshop Program Adobe Systems Incorpo-
.rated, Mountain View, CA and are means of tripli-
cate experiments"SD. RNA loading was corrected
 .using a GAPD cDNA ATCC, Rockville, MD as
control.
3. Results
It has been already shown that 72 h after the
w xadministration of a single dose of CCl 32 to pro-4
duce acute liver injury in rats, or after the induction
w xof an acute phase response episode 23 , steady-state
 .levels of liver a1 I procollagen mRNA increase
during the first 6–12 h, and return to normal values
by 24–48 h. Thus, to analyze only the chronic effects
Fig. 2. Liver collagen content was determined after elution of the
two dyes from triplicate slides obtained from at least three livers
of each group after determining the absorbance of each dye at
 .  . w x540 Sirius Red and 605 Fast green 25 . Values are means"SD
and are expressed as mg of collagenrmg protein.
 .  .  .  .  .  . Fig. 1. Representative liver sections of animals in groups 1 control A , 2 turpentine-treated B , 3 CCl -treated C and 4 treated4
. . w xwith turpentineqCCl D stained with Picrosirius red and Fast green 25 . Collagen fibers are stained in red and the rest of the section4
is stained in light green. Arrows pointing at collagen fibers show that those in group 4 are thicker in diameter than those in group 3.
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produced by the various experimental conditions used,
all animals were sacrificed either one week after the
last induction of the acute phase response episode or
72 h after the last dose of CCl .4
Histologic analysis of livers obtained from turpen-
tine-treated animals showed no overt liver pathology
and were similar to control untreated rats see Fig.
.1A and 1B . On the other hand, livers of animals
 .treated with CCl Fig. 1C or CCl q turpentine4 4
 .Fig. 1D showed areas of necrosis, steatosis and
fibrosis. However, animals in group 4 contained more
fibrosis and less steatosis as those in group 3. In
Fig. 3. Representative Northern blot performed with 10 mg of
total RNA obtained from livers of control, turpentine-, CCl - and4
 .turpentineqCCl -treated rats, hybridized with cDNAs for a1 I4
 .and a1 III procollagens, fibronectin and TIMP-1. Ethidium
 .bromide staining ETBr is shown as control for loading. Hy-
bridization and washing conditions were performed as described
in Section 2.
 .  .Fig. 4. Quantitative analysis of a1 I and a1 III procollagen
and fibronectin transcripts expressed by livers of control, turpen-
tine-, CCl - and turpentine plus CCl -treated rats. Signal intensi-4 4
ties were determined by laser densitometric analysis see Meth-
.ods and values represent means of triplicate experiments and are
expressed as arbitrary units after correcting for loading using the
signal generated after hybridization with a GAPD cDNA.
animals of group 4, steatosis was diffuse, but affected
predominantly zone 3 of the hepatic acinus.
Picrosirius staining revealed strong staining of col-
lagen fibers in portal and perivenular areas in control
 .  .Fig. 1A and turpentine-treated animals Fig. 1B .
However, collagen content within the parenchyma
was low and only a few scattered thin fibrils were
 .seen at higher magnification not shown . The loca-
tion and extent of collagen staining was similar in
both control groups. Livers of animals treated with
 .  .CCl group 3 Fig. 1C contained more collagen4
fibers than those of the control and turpentine-treated
groups. Thin collagen fibers irradiated from vascular
regions and, in a few areas, there was formation of
septa. Animals receiving the combined treatment of
turpentine plus CCl contained more liver collagen4
 .than those in group 3 Fig. 1D . In general, collagen
fibers were thicker and formation of septa occurred
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with higher frequency than in livers of rats in group 3
 .Fig. 1C . Quantitative analysis of liver collagen
concentration determined by the Sirius redrFast green
w x  .procedure 25 see Fig. 2 , revealed that control
livers contained 7.3"1.5 mg of collagenrmg pro-
tein. These data are consistent with those previously
w xreported in the literature 25 . In rats receiving only
turpentine, liver collagen content was similar to that
of control animals 7.6"1.9 mg collagenrmg pro-
.tein . On the other hand, and as expected, liver
collagen content of rats treated with CCl was in-4
creased 10.1"2.4 mgrmg protein, P-0.05 com-
.pared to controls . Moreover, in animals receiving the
combined treatment, liver collagen was further in-
 .creased 13.2 mgrmg protein and the values were
significantly higher from those obtained in the other
 .three groups P-0.003 .
The changes in liver collagen content described
above correlated with modifications in the expression
 .  .of a1 I and a1 III procollagen mRNAs. As shown
 .  .in Fig. 3, a1 I and a1 III procollagen mRNAs
were undetectable in total RNA extracted from con-
trol or turpentine-treated rats, but were readily de-
tectable in livers of animals receiving either CCl4
alone or CCl q turpentine. However, while expres-4
Fig. 5. Quantitative analysis of MMP-1 and TIMP-1 mRNAs
expressed by livers of control, turpentine-, CCl and turpentine4
plus CCl -treated rats. Signal intensities were determined as4
described in Fig. 4. Values are means of triplicate experiments
and are expressed in arbitrary units after correction for loading.
 .sion of a1 I procollagen mRNA was further in-
duced in livers of animals receiving the combined
 .treatment group 4 as compared to those receiving
 .  .CCl alone group 3 , the expression of a1 III4
procollagen mRNA was slightly lower in the former
 .see Fig. 4 as compared to the latter group. Like-
 .wise, expression of MMP2 mRNA Fig. 5 was in-
creased in rats receiving the combined treatment, but
was not significantly different from values obtained
in rats from group 3. As also shown in Figs. 3 and 4,
the expression of fibronectin mRNA was similar in
all the groups. It is noteworthy to mention that the
 .expression of TIMP1 mRNA Fig. 5 closely mimics
 .the alterations observed in a1 I procollagen mRNA.
This mRNA was very low in control and turpentine-
treated animals, increased significantly in animals
receiving CCl and was further increased in those4
receiving the combined treatment.
4. Discussion
Chemical and biological agents that induce injury
trigger defined sets of local and systemic responses in
the affected host that include, among others, inflam-
matory and immunological responses. In general,
these responses are beneficial and result in complete
normalization of the affected tissue and in restoration
w xof the systemic homeostatic mechanism 1,2 . How-
ever, under certain conditions, the triggered inflam-
matory and immunological reactions are noxious for
the host, and thus, either contribute to the injurious
process or are directly responsible for sequelae. De-
w xposition of immune complexes 33 , and of amyloid
w x34 in various organs, are two general examples of
disease states resulting from the general response of
the host to injury.
The exact mechanisms by which the APR con-
tributes to fibrosis are unknown. It has been sug-
gested that the simultaneous administration of
bleomycin and an APR-inducer, enhances the devel-
w xopment of pulmonary fibrosis in rats 35 . Similarly,
the administration of CCl and an APR-inducing4
agent, accelerates the development of liver fibrosis
w x36–38 . It was suggested that proteins induced dur-
ing the APR, such as a 2-macroglobulin andror the
induction of prolylhydroxylase, an enzyme needed
for conversion of protein-bound prolyl to hydrox-
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yprolyl-residues, were directly responsible for excess
w x w xdeposition of collagen 37 . Our previous 23 and
 .current results this communication strongly support
the notion that cytokines produced during the APR
w xhave a direct effect on organ fibrosis. We 10,21 and
w xothers 19 , have shown that LSC express IL-6 mRNA
and protein. Similarly, others have demonstrated that
w xhepatocytes 5,39 and isolated Kupffer cells express
w xIL-6 5,11 . We have further shown that LSC respond
 .to this cytokine with increased expression of a1 I
procollagen mRNA and that this response is different
in LSC derived from normal liver as compared with
those isolated from CCl -cirrhotic rat liver. In LSC4
derived from normal liver, IL-6 induced the expres-
 .sion of a1 I procollagen mRNA 2-fold and had no
effect on steady state levels of TGF-b1 mRNA.
However, in LSC derived from cirrhotic liver, IL-6
 .induced the expression of a1 I procollagen mRNA
w x3-fold and TGFb 1 mRNA 2-fold 23 . These results
suggest that the induction of a single episode of APR
in animals with activated mesenchymal cells lung
.fibroblasts or LSC can directly contribute to pathol-
ogy by enhancing the deposition of collagen by two
distinct but complementary mechanisms. Firstly, IL-6
will induce the expression of collagen and TGF-b
mRNAs and proteins and the latter will further en-
hance collagen production via an autocrine mecha-
nism. Secondly, increased production of TGF-b will
decrease the expression of metalloproteinases in-
w xvolved in collagen degradation 40 , thus further en-
hancing collagen deposition.
In this communication we show that weekly induc-
tions of APR episodes in normal rats for three weeks,
have neither an overt effect on liver morphology nor
 .stimulate sustained expression of a1 I procollagen
w xmRNA in their livers. As already reported 23 , the
 .IL-6 effect on a1 I procollagen gene expression is
transient and mRNA levels return to normal values
by 24–48 h. In contrast to these findings, the super-
imposition of APR episodes in rats receiving CCl to4
produce cirrhosis, duplicates the amount of liver col-
 .lagen and increases the expression of a1 I procolla-
gen and TIMP-1 mRNAs. Thus, enhanced collagen
deposition in this animal model of liver cirrhosis
could result from increased production of this matrix
protein by LSC and by inhibition of its degradation in
the extracellular matrix by the MMP-1 inhibitor,
TIMP-1.
The effect of turpentine had some specificity, since
not all the mRNAs whose steady-state levels were
increased in CCl -cirrhotic livers, such as those for4
 .a1 III procollagen and MMP2, were further in-
creased by the induction of APR episodes in CCl -4
treated rats. An additional and unexpected finding of
our current studies was that fibronectin mRNA was
not modified either by CCl , or turpentine treatments.4
The lack of changes in fibronectin mRNA were
unexpected, since this protein is one of the first
extracellular matrix components to accumulate in
w xinjured livers 41 .
Our previous work has shown that the induction of
an acute phase episode in rats upregulates the expres-
 .sion of liver a1 I procollagen mRNA, that LSC are
the responsible cells, and that IL-6 is the cytokine
w xdirectly responsible for this effect 23 . Furthermore,
the intravenous administration of a neutralizing anti-
body to IL-6 prevents several of the liver manifesta-
tions of the acute phase response, including increased
 .expression of a1 I procollagen and fibrinogen mR-
w xNAs 23 . We also showed that colchicine, a drug
that inhibits the release of cytokines by circulating
w xblood mononuclear cells 42,43 , is only effective in
 .preventing the expression of a1 I procollagen
mRNA in the liver, when administered during the
first 3–5 h post-turpentine administration, at the time
that maximal blood cytokines levels have been re-
w xported 44 .
The data reported in this communication appear to
indicate that the enhancement of liver fibrosis ob-
served in rats treated with CCl plus weekly APR4
episodes is not due to turpentine-induced liver toxic-
ity, but rather to cytokines produced during the APR.
.This suggestion is based on two observations: a the
lack of overt liver damage in rats receiving turpentine
 .alone or its exacerbation necrosis andror steatosis
.in animals receiving the combined treatment, and b
 .the selective overexpression of a1 I procollagen and
TIMP-1 mRNAs in animals receiving the combined
treatment as compared with those receiving either
agent alone. However, further studies are needed to
rule out completely a direct toxic effect of turpentine
on the liver.
CCl induces liver injury by several mechanisms4
that include lipid peroxidation and formation of reac-
w xtive oxygen intermediates 45,46 . It has been shown
that aldehydes derived from lipid peroxidation induce
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w xtype I collagen gene expression in fibroblasts 47
w xand liver stellate cells 48 . Moreover, antioxidants
such as a-tocopherol prevent hepatic fibrosis induced
w xby CCl 49 . As shown in this communication, livers4
of rats receiving only CCl have diffuse steatosis and4
those receiving the combined treatment had signifi-
cantly less steatosis and more fibrosis. Therefore, it is
possible that the cytokines of the acute phase re-
sponse enhance lipid peroxidation directly, or indi-
rectly via production of TGF-b1, and by this addi-
tional mechanism contribute to liver fibrosis.
 .The cytokine s responsible for the observed ef-
fects needs also to be determined. Although our
previous results established that IL-6 was the cy-
tokine responsible for the acute effects of the APR
w x23 , this needs to be confirmed for the chronic
experiments reported in this communication. More-
over, further work is needed to establish whether the
observed effects are induced by cytokines produced
by circulating blood monocytes andror by the vari-
ous classes of cells present in the liver. Nevertheless,
irrespective of which is the APR cytokine that en-
hances fibrogenesis, and which are the cells that
produce it, our data suggest that any pathological
situation accompanied by increased production of
APR cytokines will result in acceleration of organ
fibrosis.
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